Trial Profile
Target attainment of Cefazolin Continuous Infusion for Antibiotic Prophylaxis in patients undergoing CABG surgery
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 May 2019
Price :
$35
*
At a glance
- Drugs Cefazolin (Primary) ; Dalbavancin (Primary)
- Indications Postoperative infections
- Focus Therapeutic Use
- 18 May 2019 Planned End Date changed from 30 Aug 2038 to 11 May 2022.
- 18 May 2019 Planned number of patients changed from 16 to 8.
- 18 May 2018 New trial record